semaglutide sammamish GLP-1 Receptor Agonist Research Reference Semaglutide for weight loss |

This clinical trial represents a major advance in the treatment of obesity, because semaglutide has been approved to treat type 2 diabetes in low doses, so doctors are already familiar with its usage

Clinical trial outcomes (15% weight loss for Wegovy, 20% for Zepbound) are from studies of FDA-approved products under controlled conditions - they don't predict compounded product results or any individual's outcome

Doubling the dose at one time significantly increases the likelihood of GI side effects without proportional benefit and is not supported by any trial data

The other benefit of gradual escalation is finding your optimal dose

Siegel RL, Giaquinto AN, Jemal A